Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Samir Qurashi"'
Autor:
Gady Cojocaru, Margaret L. Tang, Patrick Wall, Sandeep Kumar, Eran Ophir, Hsin-Yuan Cheng, John J. Hunter, Ling Leung, Andrew W. Drake, Maya F. Kotturi, Masha Frenkel, Kathryn Logronio, David Bernados, Moran Galperin, Kyle Hansen, Spencer Liang, Samir Qurashi, Mark A. White, Zoya Alteber, Sarah Whelan
Publikováno v:
Cancer Immunology, Immunotherapy. 70:3525-3540
Immune checkpoint inhibitors (ICIs) have emerged as promising therapies for the treatment of cancer. However, existing ICIs, namely PD-(L)1 and CTLA-4 inhibitors, generate durable responses only in a subset of patients. TIGIT is a co-inhibitory recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3956f7736390726882c24308715f5566
https://doi.org/10.1007/s00262-021-02921-8
https://doi.org/10.1007/s00262-021-02921-8
Autor:
Jane Tian, Samir Qurashi, Christina Song, Lauren Rocha, Kalyani Mondal, Suzanne Crawley, Sara Medfisch, Peirong Krisney Chen, Julie Roda, Jon Sitrin, Carmence Ho, Jonathan Aguayo, Lee Rivera, Jiawei Huang, Vicky Lin, David Shen, Yan Wang, Hui Tian, Alan Kutach, James Sissons, Daniel D. Kaplan, Geoffrey W. Stone
Publikováno v:
Cancer Research. 82:664-664
Background: Immune suppression in the tumor microenvironment is known to contribute to tumor immune evasion. ILT2 (aka LILRB1) and ILT4 (aka LILRB2) are distinct ITIM-containing immunosuppressive receptors that recognize the shared ligand MHC-I. Both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::368db876adbb2c14ffeff34423c25f27
https://doi.org/10.1158/1538-7445.am2022-664
https://doi.org/10.1158/1538-7445.am2022-664